ROLE OF DEHYDROEPIANDROSTERONE HORMONE IN RELIEVING OF VASOMOTOR SYMPTOMS IN POST AND PERI MENOPAUSE WOMEN

Abstract

Background: A numebr of medications and vitamins have been evaluate for the management of vasomotor symptoms in association with menopause, such as dehydroepiandrosterone (DHEA), black cohosh, vitamin E, evening primrose oil and phytoestrogens (19). Despite, the long list of agents used to treat these symptoms, none of the treatment was proved to be effective in all treated women. Little is known about the efficacy and safety of using DHEA in treating these symptoms in Iraqi women.
The study aim: Goal of this projectis to figure out the associated efficacy and safety of DHEA in management of vasomotor complains in a sample of Iraqi females in the peri- and post-menopausal period.
Patients and methods: This trial was a single center randomized controlled clinical trial designed as single blinded and parallel groups with an allocation ratio of 1:1 (DHEA group: placebo group). Women in the intervention group (DHEA group) were given DHEA in a dose of 50 mg orally for 4 months; whereas, women in the placebo group were given placebo tablets for 4 months. The Patients enrolled were from various regions of Adiwaniyah Province, Iraq visiting Adiwaniyah Pediatric and Maternity Teaching Hospital during the period from January 2022 through January 2023.
Results: In post and peri-menopausal females, and in all enrolled women, we reported no difference that is statically matter in mean frequencies of host flushes and night sweat in the placebo groups; however, there was significant reduction in mean frequencies of host flushes and night sweat after treatment in the interventional groups with baseline state (p< 0.001).
Conclusion: dehydroepiandrosterone appears to be safe and efficient in reducing and reliving vasomotor symptoms in peri-menopausal and post-menopausal Iraqi women.